hypertrophy and attenuates muscle weakness. It may increase urethral pressure by facilitating recovery of injured muscles in a dual injury (DI) SUI rat model. METHODS: Rats were anesthetized and underwent pudendal nerve crush (PNC) followed by vaginal distension (VD). One week after surgery, each rat began treatment via subcutaneous injection (0.3ml/ rat) once daily in a blinded fashion with either bimagrumab (DIþBim), clenbuterol (DIþCle), 5-hydroxybenzothiazolone derivative, a novel b2 adrenoceptor agonist with superior skeletal muscle selectivity in rodents compared to clenbuterol (DIþ5-HOB), or PBS (DIþSham). Sham rats underwent sham PNCþVD and received PBS (SI). Body weight was monitored weekly after injury. After two weeks of treatment, the rats were anesthetized for leak point pressure (LPP) and external urethral sphincter (EUS) electromyography (EMG) recordings. Hind limb skeletal muscles (quadriceps, gastrocnemius complex, tibialis anterior) were dissected and weighed.
INTRODUCTION AND OBJECTIVES:
The female symptoms score (FSS) is a novel phenotype developed to assess the severity of overactive bladder (OAB) in women based on 7 domains known to positively correlate with urologic systems (cardiovascular, obesity, diabetes, neurologic, sleep apnea, stress/anxiety, and vaginal atrophy). Scores range from 0-14 with higher values reflecting greater comorbidity. We hypothesized that higher scores predicted progression to second and third-line therapy.
METHODS: Women undergoing treatment for OAB at a large tertiary center from February 2018 to August 2018 were identified. A score from 0-2 (0[mild, 1[moderate, 2[severe) was given for each FSS category. A total FSS was the sum of all 7 categories. Total FSS were further stratified into low (0-4), moderate (5-9), and high (10) (11) (12) (13) (14) . Primary outcome measures were use of pelvic floor physical therapy (PFPT), number of medications prescribed, and progression to third-line OAB therapy -intradetrusor onabotulinumtoxinA injection (BTXa) vs. sacral neuromodulation (SNM). Descriptive and comparative statistics were calculated, with statistical significance set at p<0.05.
RESULTS: The mean FSS was 5.5AE2.63 (n[307) for the sample. FSS correlated positively and significantly with the number of medications prescribed (R: 0.286, p<0.01) and progression to third line OAB therapy (R:0.116, p<0.01). With stratification, a higher FSS suggested use of more than one medication -denoted as OAB polypharmacy (mild: 25.2% < moderate: 64.3% < severe: 72.4%, p<0.01 ). A moderate FSS was significantly associated with greatest SNM use (mild: 1.7% < severe 4.5% < moderate 6.5%, p[0.04). Obesity was associated with both OAB polypharmacy and third line therapy (p[0.04, 0.02, respectively); Cardiovascular, stress/anxiety, neurologic, and vaginal atrophy components were associated with progression to third-line therapy (all p<0.01). No significant relationships were noted between FSS and PFPT, BTXa injection, or mirabegron use.
CONCLUSIONS: FSS is easily calculated and may help determine likelihood of progression to second and third line therapy for patients with OAB. Patients with a higher burden of systemic disease as measured by a higher FSS were more likely to require polypharmacy or third-line therapy.
Source of Funding: None

PD36-12 CHARACTERIZATION OF SAFETY EVENTS FOR ENERGY-BASED DEVICES FOR TREATMENT OF VAGINAL SYMPTOMS: AN ANALYSIS OF THE FOOD AND DRUG ADMINISTRATION MANUFACTURER AND USER FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE FROM 2013 TO 2016
Shannon Wallace*, Ekene Enemchukwu, Stanford, CA INTRODUCTION AND OBJECTIVES: Energy-based devices have gained momentum as minimally invasive procedures to stimulate collagen regeneration in the female lower genital tract and treat vaginal symptoms related to menopause, urinary incontinence or sexual dysfunction. However, the FDA recently issued a statement cautioning patients and providers that the safety and efficacy of energy-based devices for the treatment of vaginal symptoms has not been well established. The existing data on side effects is insufficient and limited to observation studies. We sought to characterize the safety events of vaginal energy devices by analysis of surveillance data from the FDA Manufacturer and User Facility Device Experience (MAUDE) database.
METHODS: The MAUDE database was queried between September 30, 2013 and September 30, 2018 for all energy-based vaginal devices. The incidence of safety events was reported for these devices and the most common complaints were described and characterized.
RESULTS: Twenty-seven unique and relevant medical device reports were retrieved for vaginal energy based devices including Mona Lisa Touch (Cynosure, Westford, MA) (13/27; 48.1%), diVa (Sciton, Palo Alto, CA) (3/27; 11.1%), ThermiVa (ThermiGen, Irving, TX) (5/27; 18.5%), FotonaSmooth (Fotona, Dallas, TX) (1/27; 3.7%) and FemTouch (Lumenis, San Jose, CA) (5/27; 18.5%). Five reports were filed in 2016 (18.5%), six in 2017 (22.2%) and sixteen in 2018 (59.3%). Within the reports there were 53 different complaints. The most common complaints were vaginal pain (15/27; 55.6%), dyspareunia (6/27; 22.2%), bladder pain (4/27; 14.8%) and urinary frequency (3/27; 33.3%). (Table 1) CONCLUSIONS: MAUDE-reported data shows these patients who receive treatment with energy-based vaginal devices are still at risk for vaginal pain, bladder pain and urinary symptoms. Additional studies are needed to understand the risk profile and complication rates of the available energy-based therapies. This data will better help guide providers to promote effective and safe treatments of pelvic floor conditions.
